Bristol-Myers Squibb Company (BMY) News
Track canonical SquawkNews coverage tagged to BMY, Bristol-Myers Squibb Company. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 86 indexed stories across 33 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Bristol Myers Squibb declares $0.63 quarterly dividend
Bristol Myers Squibb announced its board declared a quarterly dividend of $0.63 per share on its $0.10 par value common stock, payable November 2, 2026 to stockholders of record as of the close of business.
EQUITY | Sep 16, 2026, 10:59 AM UTC
M
Bristol Myers, Ono sue Amgen to block Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court seeking to block Amgen’s proposed U.S. biosimilar of Opdivo.
EQUITY | Sep 15, 2026, 08:25 PM UTC
L
Bristol Myers sues Amgen over proposed Opdivo biosimilar
By Blake BrittainBristol Myers Squibb NYSE:BMY and Ono Pharmaceutical TSE:4528 have sued Amgen NASDAQ:AMGN in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunoth
NEWS | Sep 15, 2026, 05:29 PM UTC
L
Undervalued healthcare stocks with attractive valuation grades
Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotechnology firms and healthcare services businesses navigate changing demand and industry conditions.With v
NEWS | Sep 15, 2026, 05:21 PM UTC
L
HBA India Summit Calls For Leaders To Command The AI Shift
Hyderabad summit highlights AI, GCCs, commercial acumen and influence as India takes on a larger role in global healthcare leadershipThe Healthcare Businesswomen’s Association (HBA) India hosted the third edition of its
NEWS | Sep 15, 2026, 08:32 AM UTC
H
AM Markets Need to Know: Diesel tops $6, DeepSeek pressures chips, and more
Stock index futures were higher on Friday as investors awaited the consumer inflation report, while Oracle posted stronger-than-expected quarterly results and guidance.Here are the five news items investors should watch:
MACRO | Sep 11, 2026, 10:01 AM UTC
L
Bristol-Myers Squibb Is Maintained at Hold by HSBC
Ratings actions from Benzinga
EQUITY | Sep 10, 2026, 02:08 PM UTC
L
Bloomsbury Publishing director/PDMR sale following 2023 ESP option vesting and exercise
Bloomsbury Publishing PLC said director/PDMR shareholdings were sold following the vesting and exercise of options under its 2023 Executive Share Plan (2023 ESP). The RNS is dated 10 September 2026.
EQUITY | Sep 10, 2026, 11:06 AM UTC
L
25 dividend stocks to watch as market sentiment turns negative
Dividend-paying stocks gained renewed momentum Wednesday as investors shifted toward safety amid a slide in broader market averages.The blue-chip Dow Jones Industrial Average TVC:DJI dropped to a new one-month low while
ENERGY | Sep 09, 2026, 04:51 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
M
Bristol Myers reports positive Phase 2 QUINTESSENTIAL myeloma results
Bristol Myers Squibb announced positive Phase 2 registrational QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multi
EQUITY | Sep 08, 2026, 02:26 PM UTC
M
Bristol Myers cell therapy for multiple myeloma meets main goal
Bristol Myers Squibb said its experimental cell therapy arlocabtagene autoleucel (arlo-cel) met the main goal in a mid-stage trial in patients with a hard-to-treat form of multiple myeloma.
EQUITY | Sep 08, 2026, 11:12 AM UTC
M
Bristol Myers Squibb cell therapy meets mid-stage trial goal
BMY said its experimental cell therapy met the main goal of a mid-stage trial.
EQUITY | Sep 08, 2026, 11:03 AM UTC
L
Bloomsbury Publishing's Succession Plan Isn't Surprising — Market Talk
Bloomsbury Publishing's succession plan shouldn't come as a surprise, Peel Hunt's Jessica Pok and Melanie Yang write in a note. The London-listed publishing company outlined a five-year leadership succession as founder a
EQUITY | Sep 08, 2026, 10:11 AM UTC
L
Bloomsbury CEO Nigel Newton Becomes Exec Chair, Co To Name New Chief In Two Years
Bloomsbury Publishing PLC LSE:BMY
EQUITY | Sep 08, 2026, 06:18 AM UTC
L
Bloomsbury Publishing: Majority of Bd Will Comprise Independent Nonexecutive Directors
Bloomsbury Publishing: Majority of Bd Will Comprise Independent Nonexecutive Directors
EQUITY | Sep 08, 2026, 06:17 AM UTC
L
Bloomsbury Publishing: John Bason Moves From Chmn to Deputy Chmn
Bloomsbury Publishing: John Bason Moves From Chmn to Deputy Chmn
EQUITY | Sep 08, 2026, 06:17 AM UTC
L
Bloomsbury Publishing to Appoint New CEO in Two Years' Time
Bloomsbury Publishing to Appoint New CEO in Two Years' Time
EQUITY | Sep 08, 2026, 06:08 AM UTC
L
Bloomsbury Publishing Names Nigel Newton as Executive Chmn
Bloomsbury Publishing Names Nigel Newton as Executive Chmn
EQUITY | Sep 08, 2026, 06:03 AM UTC
L
REG - BloomsburyPublishing - Succession Plan
RNS Number: 7509T Bloomsbury Publishing PLC 08 September 2026 BLOOMSBURY PUBLISHING PLC("Bloomsbury" or "the Company")Nigel Newton becomes Bloomsbury's Executive Chairman in five-year leadership succession plan securing
EQUITY | Sep 08, 2026, 06:01 AM UTC
L
Feoh Investments UK LLP holds 3.01% in Bloomsbury Publishing as of Sept 3
Feoh Investments UK LLP holds a 3.01% stake in Bloomsbury Publishing PLC as of Sept 3, according to TradingView News.
EQUITY | Sep 04, 2026, 01:26 PM UTC
L
Bloomsbury Publishing files TR-1 major holdings notification
Bloomsbury Publishing PLC filed a TR-1 (standard form) notification of major holdings regarding an acquisition or disposal of voting rights. The notice is dated 04 September 2026.
MNA | Sep 04, 2026, 01:23 PM UTC
L
Bristol Myers Squibb pauses autoimmune trials after life-threatening side effects
Bristol Myers Squibb told regulators, researchers and patient groups in early June it paused closely watched drug research due to life-threatening side effects. The update reached the broader public three months later.
EQUITY | Sep 03, 2026, 10:00 PM UTC
L
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / / September 3, 2026 / Originally published on NCPA.orgA trailblazing new program using rural pharmacies
EQUITY | Sep 03, 2026, 01:00 PM UTC
L
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services — Barrons.com
By Doug BuschReviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. The review shows which assumptions held and which ones failed
EQUITY | Sep 03, 2026, 05:51 AM UTC
L
Bloomsbury director shareholding: awards vested and exercised under 2023 ESP
Bloomsbury Publishing Plc said it has vested and exercised awards under its 2023 Executive Share Plan, following details referenced in its annual report. (RNS dated 2 September 2026.)
EQUITY | Sep 02, 2026, 01:07 PM UTC
L
Bloomsbury Publishing director buys shares via dividend reinvestment plan
Bloomsbury Publishing says John Bason, Non-executive Chairman, purchased 206 shares on 2 September 2026 as part of a dividend reinvestment plan.
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
Bristol Myers pauses Zola-Cel review to assess clinical data
Bristol Myers spokesperson said the company implemented a voluntary pause to review clinical data across its Zola-Cel program.
EQUITY | Sep 01, 2026, 11:49 AM UTC
H
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obs
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiolog
GEOPOLITICS | Aug 29, 2026, 03:00 PM UTC
L
Pharma Industry Stares Down Biggest Patent Cliff in Decades — WSJ
Pharma Industry Stares Down Biggest Patent Cliff in Decades — WSJ
EQUITY | Aug 29, 2026, 01:09 AM UTC
L
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits
EQUITY | Aug 28, 2026, 04:45 PM UTC
L
REG - BloomsburyPublishing - Director/PDMR Shareholdings
REG - BloomsburyPublishing - Director/PDMR Shareholdings
EQUITY | Aug 26, 2026, 03:08 PM UTC
L
UBS maintains Buy on BMY ahead of Ph3 IPF review
UBS says a deep dive into BMY’s Phase 3 IPF studies is coming up and keeps a Buy rating with an $80 price target.
EQUITY | Aug 20, 2026, 11:09 AM UTC
M
Bristol-Myers Squibb shares hit highest since May 2023
Bristol-Myers Squibb shares rose to $68.11, the highest level since May 2023, after gaining 12.92% over the past 4 weeks and 40.53% in the last 12 months.
EQUITY | Aug 19, 2026, 01:45 PM UTC
M
Bristol Myers Squibb pays Atrium Therapeutics $15M milestone
Atrium Therapeutics earns a $15 million milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration, per TradeXchange Newsdesk.
MNA | Aug 13, 2026, 12:01 PM UTC
M
U.S.-China biotech rivalry drives pharma dealmaking, policy scrutiny
China has pulled ahead of the United States in two of six domains in a June Cure Innovation Index survey, while U.S. agencies and lawmakers move to screen biotech ties and licensing deals continue.
GEOPOLITICS | Aug 13, 2026, 02:41 AM UTC
H
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. re
EARNINGS | Aug 11, 2026, 12:39 PM UTC
M
Bristol Myers Squibb Builds Houston Facility
Bristol Myers Squibb creates 500+ jobs
EQUITY | Aug 10, 2026, 03:05 PM UTC
M
Bristol Myers Squibb Invests $2.3 Billion In Houston Campus
Bristol Myers Squibb invests in new campus
EQUITY | Aug 10, 2026, 01:01 PM UTC
H
AstraZeneca, Bristol Myers Squibb Deny Deal Talks
AstraZeneca and Bristol Myers Squibb deny merger discussions
MNA | Aug 05, 2026, 12:05 PM UTC
H
BMY Upgraded to Buy at Argus
BMY upgraded to buy with $75 price target
EQUITY | Aug 05, 2026, 11:52 AM UTC
H
Oil Sinks 6%, Nasdaq 100 Rallies On Iran Talks: Stock Market Today
U.S. equities opened August with a broad-based relief rally Monday as crude oil tumbled and Treasury yields retreated from 18-month highs, after President Donald Trump called off a planned military strike on Iran over th
EARNINGS | Aug 03, 2026, 05:05 PM UTC
H
BMY AZN - pre-mkt note: W hile BMY-AZN merger could make sense for BMY at right price, AZN investors may find it hard to swallow given upcom
BMY AZN - pre-mkt note: W hile BMY-AZN merger could make sense for BMY at right price, AZN investors may find it hard to swallow given upcoming LOEs and significant pipeline risk. Wells sees FTC and geopolitics as the gr
MNA | Aug 03, 2026, 02:54 PM UTC
L
BMY Down 1.6%
BMY shares decline
EQUITY | Aug 03, 2026, 02:50 PM UTC
H
BMY AZN - pre-mkt note: FT Reports Mega-Merger Talks: Potential AZN-BMY Combination Would Be Large... and Very Complex; Maintain Sector Perf
BMY AZN - pre-mkt note: FT Reports Mega-Merger Talks: Potential AZN-BMY Combination Would Be Large... and Very Complex; Maintain Sector Perform, $64 on BMY @ RBC
MNA | Aug 03, 2026, 02:42 PM UTC
H
BMY Erases Gains On AZN M&A Reports
BMY shares drop after M&A reports with AZN
MNA | Aug 03, 2026, 02:13 PM UTC
H
Astrazeneca in talks to merge with Bristol Myers
Astrazeneca and Bristol Myers discuss merger
MNA | Aug 03, 2026, 01:19 PM UTC
H
Fed's Williams: Policy Well Positioned
Fed's Williams believes policy is well positioned for 2% inflation target
EARNINGS | Aug 03, 2026, 11:31 AM UTC
H
BMY shares rise 6% premarket on reports AZN held preliminary talks about a possible merger that would create one of the world's biggest Phar
BMY shares rise 6% premarket on reports AZN held preliminary talks about a possible merger that would create one of the world's biggest Pharmaceutical companies with a combined value of nearly $400B, a person familiar wi
MNA | Aug 03, 2026, 10:13 AM UTC
H
AstraZeneca Falls 7.3% On Bristol Myers Squibb Talks
AstraZeneca shares drop on potential combination talks
MNA | Aug 03, 2026, 09:53 AM UTC
H
Astrazeneca, Bristol Myers Squibb Discuss Potential Merger
Astrazeneca and Bristol Myers Squibb in talks for potential combination
MNA | Aug 03, 2026, 12:02 AM UTC
H
AstraZeneca, Bristol Myers Squibb in $400bn talks
AstraZeneca and Bristol Myers Squibb discuss potential merger
MNA | Aug 02, 2026, 07:40 PM UTC
H
BMY Raise PT to $64 after posted a strong Q226 with beats across its Legacy and Growth portfolios, lifting its 2027 guidance @ RBC
BMY Raise PT to $64 after posted a strong Q226 with beats across its Legacy and Growth portfolios, lifting its 2027 guidance @ RBC
EQUITY | Jul 31, 2026, 12:05 PM UTC
M
LLY, BMY Invest in Ratio Therapeutics
LLY and BMY invest in Ratio Therapeutics
EQUITY | Jul 31, 2026, 12:03 PM UTC
L
REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug fo
REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug for a type of skin cancer. REPL seeks accelerated approval for RP1 in combination
REGULATION | Jul 31, 2026, 10:52 AM UTC
H
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
Bristol-Myers Squibb Co. (NYSE: BMY ) shares are up on Thursday as the company reported its second-quarter financial results for 2026. • Bristol-Myers Squibb stock is showing upward movement. Why are BMY shares climbing?
EARNINGS | Jul 30, 2026, 06:11 PM UTC
H
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.40% to 51,801.63 while the NASDAQ surged 2.08% to 24,952.56. The S&P 500 also rose,
EARNINGS | Jul 30, 2026, 04:02 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
H
BMY Delays Atrial Fibrillation Trial Data
BMY delays trial data to Q1 2027
EQUITY | Jul 30, 2026, 12:29 PM UTC
H
Bristol-Myers Squibb Raises FY2026 Adj EPS Guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 Est; Raises FY2026 Sales Guidance from $46.000B
Bristol-Myers Squibb (NYSE: BMY ) raises FY2026 Adj EPS guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 analyst estimate. Raises FY2026 sales outlook from $46.000 billion-$47.500 billion to $49.000 billion-$50.000 bill
EARNINGS | Jul 30, 2026, 11:03 AM UTC